Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Trial of Lu AH69593 in Healthy Participants

ClinicalTrials.gov ID: NCT07775261

Public ClinicalTrials.gov record NCT07775261. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 2:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Interventional, Open-label, Fixed-sequence Crossover Trial Investigating the Effect of CYP3A4/5 Modulation on the Pharmacokinetics, Safety and Tolerability of Lu AH69593 and the Effect of Lu AH69593 on the Pharmacokinetics of a CYP3A4/5 Substrate in Healthy Participants

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This trial will evaluate the effects of itraconazole (Part A) and, carbamazepine (Part B) on Lu AH69593, and the effect of Lu AH69593 on midazolam (Part C) in adult healthy participants. The main goals of this trial are to learn about 1. the effect of other medicines on Lu AH69593 2. the pharmacokinetic parameters of Lu AH69593 (how the drug is absorbed, distributed, and processed by the body), and 3. the safety and tolerability of Lu AH69593.

Study identification

NCT ID
NCT07775261
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 1
Lead sponsor
H. Lundbeck A/S
Industry
Enrollment
46 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years to 55 Years
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 27, 2026 (Actual)
Primary completion
Nov 4, 2026 (Estimated)
Completion
Nov 6, 2026 (Estimated)
Last update posted
Oct 14, 2026

2026

United States locations

U.S. sites
1
U.S. states
1
U.S. cities
1
Facility City State ZIP Site status
Fortrea Clinical Research Unit Ltd (Labcorp Clinical Research Unit Limited) Madison Wisconsin 53704-2526 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07775261, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 14, 2026 · Synced Oct 17, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT07775261 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →